P1.18-01 RELAY EU/US Subset: Ramucirumab Plus Erlotinib Improves Progression-Free Survival in First-Line EGFR Mutation-Positive NSCLC
Journal of Thoracic Oncology(2019)
关键词
EU/US subset,EGFR-mutation positive NSCLC,Ramucirumab
AI 理解论文
溯源树
样例

生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要